Navigation Links
Cord Blood America Posts Letter to Shareholders: New Administration's Potential Enhanced Stem Cell Research Initiative Should Benefit the Company and Its Shareholders
Date:11/13/2008

SANTA MONICA, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that a letter to shareholders from CEO Matthew Schissler has been posted on the Company's website. The letter explains some of the positive scientific and economic implications of the potential enhanced stem cell research initiatives proposed by the new Obama Administration.

On Sunday, November 9, 2008, John Podesta, who is leading President Elect Barack Obama's transition team, told Fox News (http://www.foxnews.com/story/0,2933,449164,00.html):

"We're looking at -- again, in virtually every agency to see where we can move forward, whether that's on energy transformation, on improving health care, on stem cell research.

There's a lot that the president can do using his executive authority without waiting for congressional action, and I think we'll see the president do that ..."

Mr. Schissler commented, "Because of this interview, there seems to be a rejuvenated and heightened awareness to stem cells and the philosophy change that is anticipated from our President Elect. It is my hope that, through a series of communicative letters to shareholders and families alike, that CBAI can provide valuable information from both a macroeconomic perspective, as well as a direct relation to the individual."

"I am often asked the question: 'What does this mean for Cord Blood America?'" Mr. Schissler said. "Families ask us: 'What does this mean for my family, should I store stem cells, what are the differences between embryonic and adult stem cells, and what does the research mean to our medical community and our economy?'"

"We believe the letter that was posted today and which can be accessed at http://www.cordblood-america.com will help answer some of these questions," Cord Blood America's CEO said. "In summary, we believe that an infusion of capital into stem cell research and development will lead to more therapies being commercialized, a higher percentage of families benefiting from these therapies and, subsequently, a higher percentage of families choosing to store stem cells. We believe this is a significant positive for both stem cell companies and our shareholders."

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at http://www.corcell.com. For investor information, visit http://www.cordblood-america.com.

Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

CONTACT:

Paul Knopick

E & E Communications

949/707-5365

pknopick@eandecommunications.com


'/>"/>
SOURCE Cord Blood America, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Education Program Spurs Blacks to Take Blood Pressure Meds
2. Documentary Examining Deadly Blood Disorders and Lifesaving Research to Premiere on Discovery Health
3. Over 50 percent of people with high blood pressure unaware they have condition
4. Documentary Examining Deadly Blood Disorders and Lifesaving Research to Premiere on Discovery Health
5. High Blood Fat Levels Tied to Ischemic Stroke Risk
6. Pantheon China Acquisition Corp. to Acquire China Cord Blood Services Corporation - Extension Proxy Filed With SEC
7. New Blood Test Better Identifies Heart Failure Patients in ER
8. Battling Bacteria in the Blood: U-M Researchers Tackle Deadly Infections
9. Blood pressure control inequality linked to deaths among blacks
10. Heart Valves Fashioned From Stem Cells in Umbilical Cord Blood
11. Tumors grow faster without blood-supply promoting molecule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical companies are held ... with process innovation in drug formulation and manufacturing. CoreRx offers its clients ... equipment in support of their development and manufacturing goals. , The company ...
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers ... back pain with a reputable physician in their area, announces the launch of a ... information for patients who are looking for reputable physicians to help them with back ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest ... chronic problems, I focus on preventative care with all my patients to alleviate possible future ... always feel free to contact my office and my trained staff will assist you in ...
(Date:4/25/2017)... ... April 25, 2017 , ... Emergency Physician and Distinguished Professor of Emergency ... Series, Outliers in Writing, set to publish in summer 2017. , Dr. Bobrow, ... University of Arizona College of Medicine. He also serves as Medical Director for the ...
(Date:4/25/2017)... ... ... Vetoquinol USA® , a world-class developer of veterinarian-approved ... EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin UCII ... The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and joints. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Company,s consumer product development program, based on its ... for Investigative Dermatology (SID) 76 th Annual ... promote the sciences relevant to skin health and ...
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
Breaking Medicine Technology: